Sanofi
SNYACTIVE ACQUIRERQUIETSanofi reads as an Active Acquirer (composite 49/100); Platform Builder deploying $2B across 5 disclosed transactions, newly disclosed vs the prior cycle · primary market Healthcare.
Lens
Disclosed M&A capital (2023–2025)
$2B
vs N/A in 2020–2022
Disclosed transactions
5
2/3 active fiscal years in window
Buyer archetype
Platform Builder
Large and recent disclosed spend expands platforms or service-line scale.
Composite score
49
Active Acquirer dominates · Quiet
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
DominantCompanies actively deploying disclosed capital into M&A
- $22.7B disclosed buyer spend
Buyer Cadence
Buyer-side companies with recent filing activity
Target Probability
Issuers showing target-side patterns from filings
- Control-process language
- 25 activism filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
- 25 activism filings
Pressure Watch
Issuers facing activism, governance, or control pressure
- 25 activism filings
- Latest activism 4.8y ago; discounted
- Control-process filings
Distress Watch
Issuers showing financial-distress filing patterns
- Missing recent 10-Q
- 25 activism filings
Restatement Risk
Issuers with accounting-integrity flags from filings
Capital Velocity
Issuers with the highest filing-activity intensity
- 3 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $102.4B
- 4 active signals
Capital cadence.
Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.
Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $15,323M · Peak count: 5
| FY | Disclosed buys | Disclosed spend | Avg ticket | Audited tier |
|---|---|---|---|---|
| 2025 | 5 | N/A | N/A | N/A |
| 2024 | N/A | $2B | N/A | N/A |
| 2023 | N/A | N/A | N/A | N/A |
| 2022 | 1 | N/A | N/A | N/A |
| 2021 | 3 | N/A | N/A | N/A |
| 2020 | 2 | N/A | N/A | N/A |
Strategy posture.
The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.
Archetype mix
- Platform20%
- Geographic Expansion20%
- Bolt On20%
- Horizontal Consolidation20%
- Technology Acquisition20%
Strategy keywords
Terms recurring across recent 10-K acquisition disclosures.
- platform
- geographic_expansion
- bolt_on
- horizontal_consolidation
- technology_acquisition
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“As the MCOs/PBMs grow in size following market consolidation, pharmaceutical companies have faced increased pressure in discounting and usage negotiations, and competition among pharmaceutical companies to have their products included in the payers’ formularies is robust.”
“Our Consumer Healthcare (CHC) activity is supported by four strategic categories: Allergy Cough & Cold, Pain, Digestive and Nutritionals.”
“In the United States, price is increasingly important to managed care organizations (MCOs) and pharmacy benefit managers (PBMs).”
“covering approximately 85% of prescription drug claims, consolidation has led to greater PBM GPO negotiating power with drug”
“With the three largest pharmacy benefit manager group purchasing organizations (PBM GPOs) (i.e. Ascent, Zinc and Emisar) now covering over 85% of prescription drug claims, consolidation has led to increased utilization management and restrictive formularies, resulting in strong bargaining power to negotiate discounted prices, thereby adversely impacting our sales.”
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Healthcare
- Market spend (2023–2025)
- $195B
- Market spend (2020–2022)
- $253.6B
- Recent vs prior
- −23%
- Issuer rank in market
- N/A
- Share of market capital
- 0.0%
Valuation positioning
SNY trades at a -3.5-turn discount to the Healthcare peer median of 12.9×.
- EV / Revenue
- 1.7×
- Net debt / EBITDA
- N/A
- Peer median EV / EBITDA
- 12.9×
Trading comparables
FMP market data · 2026-05-10
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
AbbVie Inc.ABBV | 23.4× | 6.7× | 3.1× | $62.8B | $18B |
| 17.2× | 0.9× | 1.9× | $449.7B | $28.1B | |
Amgen Inc.AMGN | 12.9× | 6.0× | 2.6× | $37.2B | $26.7B |
| 11.7× | 0.5× | 2.5× | $200.4B | $6.4B | |
SanofiSNY | 9.4× | 1.7× | N/A | $47.4B | $2B |
| 9.3× | 1.9× | 2.8× | $76.4B | $1.3B |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Healthcare. Bars scaled to the highest EV/EBITDA in the set.
Target landscape.
Public-issuer targets that fit this buyer's archetype and target categories from filing-derived signal. Scores reflect cross-signal fit; reasons cite the EDGAR-anchored facts that drove the match.
No qualifying public-issuer targets surfaced from the current signal mix.
Stated target categories
No target categories enumerated in the audited corpus for this issuer.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)252026-02-17
- 10-Q (quarterly)0N/A
- 8-K (event)0N/A
- Proxy / DEF 14A112016-07-05
- Activism (13D / DFAN / PREC)252021-08-12
Signals on file
- elevated
Activism on file
2021-08-1225 activist filings on file (13D, DFAN14A, PREC14A series).
- info
Signal
Serial acquisition history
- info
Signal
10-K strategy themes
- info
Signal
Recent transaction activity
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.